

Tobacco in Australia

Facts & Issues

Relevant news and research

6.8 Interactions between tobacco smoke and medications

Last updated April 2022

Research:

Bilal, R, Ahmad, NS, Zaffar, S, Mazhar, MU, Siddiqui, WA, & Tariq, S. (2022). Rasagiline Pharmacokinetics in CYP1A2 Variant Healthy Smokers & Non-smokers in Different Doses. *Pak J Med Sci*, 38(3Part-1), 589-594. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/35480532>

An, H, Fan, H, Chen, S, Qi, S, Ma, B, Shi, J et al (2021). Effects of Dose, Age, Sex, Body Weight, and Smoking on Plasma Concentrations of Olanzapine and N-desmethyl Olanzapine in Inpatients With Schizophrenia. *Journal of Clinical Psychopharmacology*, 41(3), 255-259. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/33814547>

Andrade C. Schizophrenia and smoking. *Journal of Clinical Psychiatry*, 2012; 73(6):e725–e7. Available from: <https://www.ncbi.nlm.nih.gov/pubmed/22795210>

Boksa P. Smoking, psychiatric illness and the brain. *J Psychiatry Neurosci*, 2017; 42(3):147–9. Available from: <https://www.ncbi.nlm.nih.gov/pubmed/28440208>

Desai HD, Seabolt J, and Jann MW. Smoking in patients receiving psychotropic medications: A pharmacokinetic perspective. *CNS Drugs*, 2001; 15(6):469–94. Available from: <https://www.ncbi.nlm.nih.gov/pubmed/11524025>

Zevin S and Benowitz NL. Drug interactions with tobacco smoking. An update. *Clinical Pharmacokinetics*, 1999; 36(6):425–38. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/10427467>

News reports:

tobaccoinaustralia.org.au